Where can I find AZN's financial statements?

AstraZeneca PLC (AZN)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for AZN?

AstraZeneca PLC (AZN) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does AZN update its statements?

AstraZeneca PLC files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

AZN

AstraZeneca PLC

NYSE·Drug Manufacturers, General · Healthcare

$169.73$0.39+0.23%

After hours·$169.00−0.43%

Market cap$131.52B·Market closed·Jul 22 8:00 PM UTC

USD · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$37.42B+40.6%	$44.35B+18.5%	$45.81B+3.3%	$54.07B+18.0%	$58.74B+8.6%
Cost of revenue	$12.44B+134.7%	$12.39B−0.4%	$8.27B−33.3%	$10.21B+23.5%	$10.63B+4.2%
Gross profit	$24.98B+17.2%	$31.96B+27.9%	$37.54B+17.5%	$43.87B+16.8%	$48.11B+9.7%
Research & development	$9.74B+62.5%	$9.76B+0.3%	$10.94B+12.0%	$13.58B+24.2%	$14.23B+4.8%
General & administrative	$15.14B	$17.45B+15.2%	$17.68B+1.3%	$19.67B+11.2%	$19.93B+1.3%
Selling & marketing	$446.00M−96.3%	$536.00M+20.2%	$539.00M+0.6%	$555.00M+3.0%	$579.00M+4.3%
SG&A (combined)	$15.59B+31.1%	$17.98B+15.4%	$18.22B+1.3%	$20.22B+11.0%	$20.51B+1.4%
Other operating expenses	−$1.40B+19.0%	$457.00M+132.6%	$193.00M−57.8%	$56.00M−71.0%	−$381.00M−780.4%
Total operating expenses	$23.92B+48.1%	$28.20B+17.9%	$29.35B+4.1%	$33.86B+15.4%	$34.36B+1.5%
Operating income	$1.06B−79.5%	$3.76B+255.8%	$8.19B+118.1%	$10.00B+22.1%	$13.74B+37.4%
Interest income	$43.00M−48.2%	$81.00M+88.4%	$301.00M+271.6%	$345.00M+14.6%	$360.00M+4.3%
Interest expense	$1.28B+0.3%	$1.33B+4.2%	$1.59B+19.5%	$1.68B+5.9%	$1.69B+0.7%
Other income / (expense), net	−$1.32B−6.0%	−$1.26B+4.9%	−$1.29B−3.0%	−$1.31B−1.4%	−$1.34B−2.2%
Income before tax	−$265.00M−106.8%	$2.50B+1,043.8%	$6.90B+175.8%	$8.69B+26.0%	$12.40B+42.7%
Income tax expense	−$380.00M−149.2%	−$792.00M−108.4%	$938.00M+218.4%	$1.65B+75.9%	$2.17B+31.5%
Net income	$112.00M−96.5%	$3.29B+2,835.7%	$5.96B+81.1%	$7.04B+18.1%	$10.26B+45.8%

EPS (basic)	$0.16−96.7%	$4.24+2,550.0%	$7.62+79.7%	$9.08+19.2%	$13.20+45.4%
EPS (diluted)	$0.16−96.7%	$4.22+2,537.5%	$7.62+80.6%	$9.00+18.1%	$13.08+45.3%
Weighted avg shares (basic)	709,000,000	774,000,000	781,000,000	775,000,000	775,000,000
Weighted avg shares (diluted)	713,500,000	780,000,000	781,000,000	781,500,000	781,000,000

Depreciation & amortization	$4.10B+41.6%	$5.25B+28.1%	$4.93B−6.1%	$5.07B+2.7%	$5.73B+13.2%
EBITDA	$5.11B−36.8%	$9.09B+77.7%	$13.42B+47.7%	$15.44B+15.0%	$19.83B+28.4%

Frequently Asked Questions About AZN

Where can I find AZN's financial statements?: AstraZeneca PLC (AZN)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for AZN?: AstraZeneca PLC (AZN) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does AZN update its statements?: AstraZeneca PLC files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

$37.42B+40.6%

$44.35B+18.5%

$45.81B+3.3%

$54.07B+18.0%

$58.74B+8.6%

Cost of revenue

$12.44B+134.7%

$12.39B−0.4%

$8.27B−33.3%

$10.21B+23.5%

$10.63B+4.2%

Gross profit

$24.98B+17.2%

$31.96B+27.9%

$37.54B+17.5%

$43.87B+16.8%

$48.11B+9.7%

Research & development

$9.74B+62.5%

$9.76B+0.3%

$10.94B+12.0%

$13.58B+24.2%

$14.23B+4.8%

General & administrative

$15.14B

$17.45B+15.2%

$17.68B+1.3%

$19.67B+11.2%

$19.93B+1.3%

Selling & marketing

$446.00M−96.3%

$536.00M+20.2%

$539.00M+0.6%

$555.00M+3.0%

$579.00M+4.3%

SG&A (combined)

$15.59B+31.1%

$17.98B+15.4%

$18.22B+1.3%

$20.22B+11.0%

$20.51B+1.4%

Other operating expenses

−$1.40B+19.0%

$457.00M+132.6%

$193.00M−57.8%

$56.00M−71.0%

−$381.00M−780.4%

Total operating expenses

$23.92B+48.1%

$28.20B+17.9%

$29.35B+4.1%

$33.86B+15.4%

$34.36B+1.5%

Operating income

$1.06B−79.5%

$3.76B+255.8%

$8.19B+118.1%

$10.00B+22.1%

$13.74B+37.4%

Interest income

$43.00M−48.2%

$81.00M+88.4%

$301.00M+271.6%

$345.00M+14.6%

$360.00M+4.3%

Interest expense

$1.28B+0.3%

$1.33B+4.2%

$1.59B+19.5%

$1.68B+5.9%

$1.69B+0.7%

Other income / (expense), net

−$1.32B−6.0%

−$1.26B+4.9%

−$1.29B−3.0%

−$1.31B−1.4%

−$1.34B−2.2%

Income before tax

−$265.00M−106.8%

$2.50B+1,043.8%

$6.90B+175.8%

$8.69B+26.0%

$12.40B+42.7%

Income tax expense

−$380.00M−149.2%

−$792.00M−108.4%

$938.00M+218.4%

$1.65B+75.9%

$2.17B+31.5%

Net income

$112.00M−96.5%

$3.29B+2,835.7%

$5.96B+81.1%

$7.04B+18.1%

$10.26B+45.8%

EPS (basic)

$0.16−96.7%

$4.24+2,550.0%

$7.62+79.7%

$9.08+19.2%

$13.20+45.4%

EPS (diluted)

$0.16−96.7%

$4.22+2,537.5%

$7.62+80.6%

$9.00+18.1%

$13.08+45.3%

Weighted avg shares (basic)

709,000,000

774,000,000

781,000,000

775,000,000

Weighted avg shares (diluted)

713,500,000

780,000,000

781,000,000

781,500,000

781,000,000

Depreciation & amortization

$4.10B+41.6%

$5.25B+28.1%

$4.93B−6.1%

$5.07B+2.7%

$5.73B+13.2%

EBITDA

$5.11B−36.8%

$9.09B+77.7%

$13.42B+47.7%

$15.44B+15.0%

$19.83B+28.4%